Clinical Trials

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.


Study ID
Merck MK3475-587

NCT Number
NCT03486873 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0865

Principle Investigator
Dr. Andrew Pecora

Phase
III

Sponsor
Merck Sharp & Dohme Corp.


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now